A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers

JAMA Psychiatry

Volumn 70, Issue 12, 2013, Pages 1347-1354

  Sigmon, Stacey C ^a   Dunn, Kelly E ^a   Saulsgiver, Kathryn ^a   Patrick, Mollie E ^a   Badger, Gary J ^b   Heil, Sarah H ^a   Brooklyn, John R ^a   Higgins, Stephen T ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALOXONE; NALTREXONE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DETOXIFICATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; OPIATE ADDICTION; OUTPATIENT DEPARTMENT; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE ABUSE; TREATMENT RESPONSE; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 84887022516     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.2216     Document Type: Article

References (70)

1. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdose-a U. S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10-13.
2. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States. Drug Alcohol Depend. 2006;81(2):103-107.
3. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 2011;30(3):264-270.
4. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69(3):215-232.
5. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain. 2006;22(8):667-676.
6. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm. 2009;15(7):556-562.
7. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U. S. adults. Drug Alcohol Depend. 2008;94(1-3):38-47.
8. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318-1327.
9. McLellan AT, Turner B. Prescription opioids, overdose deaths, and physician responsibility. JAMA. 2008;300(22):2672-2673.
10. Substance Abuse and Mental Health Services Administration (SAMHSA). The DAWN Report: Trends in Emergency Department Visits Involving Nonmedical Use of Narcotic Pain Relievers. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2010.
11. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA. 2011;305(13):1346-1347.
12. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag; 1991.
13. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290-1297.
14. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10(11):1727-1740.
15. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend. 2004;73(3):219-226.
16. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455-470.
17. Appel PW, Ellison AA, Jansky HK, Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them. Am J Drug Alcohol Abuse. 2004;30(1):129-153.
18. Luty J. Treatment preferences of opiate-dependent patients. Psychiatr Bull. 2004;28:47-50.
19. Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340-352.
20. Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf. 2007;16(8):827-840.
21. Fortney J, Booth BM. Access to substance abuse services in rural areas. Recent Dev Alcohol. 2001;15:177-197.
22. Lenardson J, Gale JA. Distribution of substance abuse treatment facilities across the rural-urban continuum. US Department of Health and Human Services, Federal Office of Rural Health Policy. http://muskie.usm.maine.edu/ Publications/rural/wp35b.pdf. 2007. Accessed September 3, 2013.
23. Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789. doi:10.1155/2011/ 948789.
24. Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA. 2000;283(10):1337-1339.
25. Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment. J Gen Intern Med. 2007;22(4):527-530.
26. Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90(1):64-71.
27. Sigmon SC. Characterizing the emerging population of prescription opioid abusers. Am J Addict. 2006;15(3):208-212.
28. Wu LT, Woody GE, Yang C, Blazer DG. How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med. 2011;5(1):28-35.
29. Franken IH, Hendriks VM. Predicting outcome of inpatient detoxification of substance abusers. Psychiatr Serv. 1999;50(6):813-817.
30. Iguchi MY, Stitzer ML. Predictors of opiate drug abuse during a 90-day methadone detoxification. Am J Drug Alcohol Abuse. 1991;17(3):279-294.
31. Kampman KM, Pettinati HM, Volpicelli JR, et al. Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. Am J Addict. 2004;13(1):74-82.
32. Dunn KE, Sigmon SC, Strain EC, Heil SH, Higgins ST. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend. 2011;119 (1-2:1-9.
33. Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994;13(3):33-45.
34. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003-2011.
35. Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104(2):256-265.
36. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments vs pharmacological treatments for opioid detoxification [update of Cochrane Database Syst Rev. 2008;(4):CD005031]. Cochrane Database Syst Rev. 2011;(9):CD005031.
37. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35(3):192-213.
38. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence: effects in man. Arch Gen Psychiatry. 1973;28(6):784-791.
39. Abbott PJ. A review of the community reinforcement approach in the treatment of opioid dependence. J Psychoactive Drugs. 2009;41(4):379-385.
40. Azrin NH, Sisson RW, Meyers R, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry. 1982;13(2):105-112.
41. Higgins ST, Sigmon SC, Wong CJ, et al. Community reinforcement therapy for cocaine-dependent outpatients. Arch Gen Psychiatry. 2003;60(10):1043-1052.
42. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129-138.
43. Weiss RD, Potter JS, Provost SE, et al. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS). Contemp Clin Trials. 2010;31(2):189-199.
44. Feingold A, Rounsaville B. Construct validity of the dependence syndrome as measured by DSM-IV for different psychoactive substances. Addiction. 1995;90(12):1661-1669.
45. McLellan AT, Luborsky L, Cacciola J, et al. New data from the Addiction Severity Index. J Nerv Ment Dis. 1985;173(7):412-423.
46. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety. J Consult Clin Psychol. 1988;56(6):893-897.
47. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
48. Selzer ML. The Michigan Alcoholism Screening Test. Am J Psychiatry. 1971;127(12):1653-1658.
49. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence. Br J Addict. 1991;86(9):1119-1127.
50. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press; 1992:41-72.
51. Peachey JE, Lei H. Assessment of opioid dependence with naloxone. Br J Addict. 1988;83(2):193-201.
52. Armitage P. Exclusions, losses to follow-up, and withdrawals in clinical trials. In: Shapiro SH, Lewis TA, eds. Clinical Trials: Issues and Approaches. New York, NY: Marcel Dekker, Inc; 1983:99-113.
53. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction: II: physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther. 1990;47(4):525-534.
54. Gossop M, Griffiths P, Bradley B, Strang J. Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. Br J Psychiatry. 1989;154:360-363.
55. Katz EC, Schwartz RP, King SD, et al. Brief vs. extended buprenorphine detoxification in a community treatment program. Am J Drug Alcohol Abuse. 2009;35(2):63-67.
56. Kosten TR, Kleber HD. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci. 1988;42(6):635-641.
57. Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction. 2012;107(9):1621-1629.
58. Senay EC, Dorus W, Goldberg F, Thornton W. Withdrawal from methadone maintenance: rate of withdrawal and expectation. Arch Gen Psychiatry. 1977;34(3):361-367.
59. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238-1246.
60. Brands B, Blake J, Sproule B, Gourlay D, Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004;73(2):199-207.
61. Fischer B, Patra J, Cruz MF, Gittins J, Rehm J. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug Alcohol Rev. 2008;27(6):625-632.
62. Treatment Episode Data Set (TEDS): National Admissions to Substance Abuse Treatment Services: 1992-2002. DASIS series: S-23, DHHS Publication No. (SMA) 04-3965. Rockville, MD: Dept of Health and Human Services; 2004.
63. Torrington M, Domier CP, Hillhouse M, Ling W. Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. J Addict Dis. 2007;26(3):93-99.
64. Office of National Drug Control Policy (ONDCP). Vermont drug control update. www.whitehouse.gov/sites/default/files/docs/state-profile-vermont.pdf. 2008. Accessed June 29, 2011.
65. Schneider MF, Bailey JE, Cicero TJ, et al. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. Pharmacoepidemiol Drug Saf. 2009;18(9):778-790.
66. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506- 1513.
67. Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend. 2007;87(1):98-102.
68. National Survey on Drug Use and Health (NSDUH) report. Nonmedical oxycodone users: a comparison with heroin users. Office of Applied Studies publication. http://www.oas.samhsa.gov. 2005. Accessed June 29, 2011.
69. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6(10):662-672.
70. Motamed M, Marsch LA, Solhkhah R, Bickel WK, Badger GJ. Differences in treatment outcomes between prescription opioid-dependent and heroin-dependent adolescents. J Addict Med. 2008;2(3):158-164.